The next five years of pharma: Pricing, biosimilars, and specialty medicines
A report from the IQVIA Institute for Human Data Science identified areas to watch through 2023.
Blockbuster
How pharma and healthcare shifted strategies post-blockbuster drug success
Remedy Health Media’s Mike Collins discusses ways pharma and healthcare companies have shifted their strategies in the years after the success of blockbuster drugs.
Five things for pharma marketers to know: Thursday, July 28, 2016
Vertex says Orkambi is on the blockbuster track; Advent and CVC reportedly made offers to buy inVentiv Health; the FDA approves Sanofi’s Adlyxin
Five things for pharma marketers to know: Friday, March 25, 2016
Gilead to pay Merck $200 million in HCV patent infringement suit; some patients aren’t prescribed blood thinners; the FDA issues generic opioid guidance
Five things for pharma marketers to know: Wednesday, February 3, 2016
Seven potential blockbusters set to launch in 2016; Amarin case may lead to ‘misleading’ marketing; Valeant, Turing raised prices to meet preset targets
